Compare Novavax Inc (NVAX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs NEOS S&P 500 High Income ETF — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while NEOS S&P 500 High Income ETF trades at $53.52. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SPYI | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $11.19 | $54.42 |
52-Week Low | $6.22 | $47.98 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
SPYI trades at $53.65, down 0.39% on the day, with a neutral technical signal. Recent dividend distributions of $0.53-$0.54 highlight its income focus, though news articles caution about tax implications and return of capital. The ETF's covered-call strategy aims for high yield amid low S&P 500 dividend payouts.
Outlook remains mixed; high monthly income appeals, but structural risks and tax complexity warrant caution. Competition from JEPI and capital erosion concerns present headwinds, while demand for yield in retirement portfolios supports relevance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
